Shattuck Labs Announces Promising Interim Data from Phase 1B Clinical Trial of SL-172154 in Combination with Azacitidine for the Treatment of HR-MDS and TP53 Mutant AML’
Shattuck Labs, a biopharmaceutical company focused on discovering and developing transformative therapies, has released its second quarter 2024 financial results along with significant business updates. At the forefront of these updates is the encouraging interim data from their ongoing Phase 1B dose-expansion clinical trial of SL-172154 in combination with Azacitidine (AZA) for treatment in patients with frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML). This data was presented at the European Society of Hematology (EHA) 2024 Annual Meeting.’
The recent announcements underscore a positive trend observed in the clinical trial, marking a crucial advancement in the company’s efforts to address unmet medical needs in these high-risk patient populations. SL-172154, an investigational compound by Shattuck Labs, combined with Azacitidine, has demonstrated promising complete response (CR) rates as of the February 1, 2024, data cutoff. Furthermore, successful bridging of responding TP53m AML patients to hematopoietic cell transplantation has been achieved, indicating potential long-term benefits of this therapeutic strategy for patients with otherwise poor prognoses.
Positive Interim Data and Continuing Developments’
The disclosed data highlights a significant milestone for Shattuck Labs. Encouraging complete response rates in previously untreated HR-MDS and TP53m AML patients have been observed, suggesting that the investigational combined treatment has a profound effect on disease progression and patient outcomes. This finding is notably beneficial for the subset of TP53m AML patients, who traditionally have limited treatment options and poorer responses to conventional therapies.
In conjunction with this positive interim data, Shattuck Labs plans to host an investor call and webcast on June 14, 2024, at 7:30 a.m. ET, which will feature discussions led by the trial’s lead investigator. This forum will provide an opportunity for continued transparency and dialogue with stakeholders, shedding light on the anticipated next steps in the clinical development of SL-172154.
Implications for the Future’
The data presented at the EHA 2024 Congress represents a promising advancement in the treatment landscape for HR-MDS and TP53m AML patients. Successful outcomes from the Phase 1B trial not only bolster Shattuck Labs’ portfolio but also offer hope for a demographic of patients who face significant clinical challenges. As additional data from this trial unfolds, it will be crucial to monitor both the efficacy and safety profiles of SL-172154, potentially paving the way for future regulatory approvals and wider clinical application.
Shattuck Labs’ continued commitment to advancing their therapeutic candidates through rigorous clinical trials is poised to generate valuable insights and transformative outcomes in the field of hematology.
Title’: Promising Interim Results from Shattuck Labs’ Phase 1B Clinical Trial of SL-172154 with Azacitidine in HR-MDS and TP53 Mutant AML
Comments